PeptideDB

Maurocalcine TFA

CAS: F: C156H270N56O46S6.xC2HF3O2 W: 3858.55 (free base)

Maurocalcine TFA is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. Maurocal
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Maurocalcine TFA is an agonist of ryanodine receptor (RyR) channel types 1, 2 and 3 with cellular permeability. Maurocalcine TFA induces [3H]ryanodine binding on RyR1 with an EC50 value of 2558 nM. Maurocalcine TFA exhibits a apparent affinity of 14 nM for RyR2. Maurocalcine TFA can be applied to in vivo cell tracking or other cell imaging techniques[1][2][3].
Invitro Maurocalcine (100 nM, 24 小时) 增加 RyR2 对激活 [Ca2+]i 的敏感性,并降低其对抑制 [Ca2+]i 的灵敏度[1]。Maurocalcine (5 μM, 4 小时/ 24 小时) 对 HEK293 完全没有细胞毒性[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Maurocalcine TFA 相关抗体: Cell Viability Assay[3] Cell Line:
Sequence Gly-Asp-Cys-Leu-Pro-His-Leu-Lys-Leu-Cys-Lys-Glu-Asn-Lys-Asp-Cys-Cys-Ser-Lys-Lys-Cys-Lys-Arg-Arg-Gly-Thr-Asn-Ile-Glu-Lys-Arg-Cys-Arg (Disulfide bridge:Cys3-Cys17;Cys10-Cys21;Cys16-Cys32)
Shortening GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR (Disulfide bridge:Cys3-Cys17;Cys10-Cys21;Cys16-Cys32)
Formula C156H270N56O46S6.xC2HF3O2
Molar Mass 3858.55 (free base)
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. De Waard S, et al. Maurocalcin and its analog MCaE12A facilitate Ca2+ mobilization in cardiomyocytes. Biochem J. 2020 Oct 30;477(20):3985-3999. [2]. Boisseau S, et al. Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Biochim Biophys Acta. 2006 Mar;1758(3):308-19. [3]. Boisseau S, et al. Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Biochim Biophys Acta. 2006 Mar;1758(3):308-19.